Market capitalization | $29.04m |
Enterprise Value | $48.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.57 |
P/S ratio (TTM) P/S ratio | 0.34 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 5.75% |
Revenue (TTM) Revenue | $84.32m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
4 Analysts have issued a Theratechnologies Inc. forecast:
4 Analysts have issued a Theratechnologies Inc. forecast:
Aug '24 |
+/-
%
|
||
Revenue | 84 84 |
6%
6%
|
|
Gross Profit | 63 63 |
14%
14%
|
|
EBITDA | 14 14 |
195%
195%
|
EBIT (Operating Income) EBIT | 12 12 |
162%
162%
|
Net Profit | -3.16 -3.16 |
89%
89%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.
Head office | Canada |
CEO | Paul Lévesque |
Employees | 114 |
Founded | 1993 |
Website | www.theratech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.